Single-cell sequencing, including genomics, transcriptomics, epigenomics, proteomics and
metabolomics sequencing, is a powerful tool to decipher the cellular and molecular …

Understanding tumor immune microenvironments is critical for identifying immune modifiers
of cancer progression and developing cancer immunotherapies. Recent applications of …

Biological heterogeneity in diffuse large B cell lymphoma (DLBCL) is partly driven by cell-of-
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …

During adaptive immunity, B cells differentiate either into memory B cells or plasma cells and
produce antibodies against foreign antigens to fight infection. Additionally, they behave as …

Cellular deconvolution algorithms virtually reconstruct tissue composition by analyzing the
gene expression of complex tissues. We present the decision tree machine learning …

Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to …

Cancers are a group of heterogeneous diseases characterized by the acquisition of
functional capabilities during the transition from a normal to a neoplastic state. Powerful …

The activities of non-haematopoietic cells (NHCs), including mesenchymal stromal cells and
endothelial cells, in lymphomas are reported to underlie lymphomagenesis. However, our …

Diffuse large B cell lymphoma (DLBCL) is one of the most common yet aggressive types of B
cell lymphoma and remains incurable in 40% of patients. Herein, we profile the …

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and represents
the most common subtype of lymphoma. Although 60–70% of all patients can be cured by …